| Name | Title | Contact Details |
|---|
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage`s lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Cellestis Limited is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
5 hour energy is a Farmington, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FASgen is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Access Bio Inc is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.